<DOC>
	<DOCNO>NCT02954666</DOCNO>
	<brief_summary>Different approach cardio-neuroablation ( CNA ) treat neurally mediate syncope , sinus node dysfunction , functional atrioventricular block publish . Investigators develop limited specific approach CNA , call cardio-neuromodulation ( CardNM ) . This treatment base tailored vagolysis sinoatrial node partial ablation anterior right ganglionated plexus ( ARGP ) ; also base innovative anatomic strategy . The feasibility CardNM already test center limit first study human ( CardNMH1 ) , favorable outcome patient involve . The result CardNMH1 submit publication . The purpose second study CardNM human ( CardNMH2 ) collect procedural clinical data well-defined patient group .</brief_summary>
	<brief_title>Second Study Cardio-neuromodulation Humans</brief_title>
	<detailed_description>This phase II A prospective , interventional study . All patient undergo CardNM . The study involve eight different step , screen procedure study completion : screening , enrollment , pharmacological testing , group allocation , preprocedural assessment , procedure , follow-up , study completion.The dedicate study nurse PI responsible record data trial case report form ( CRFs ) complete study database . A dedicated independent physician responsible safety monitoring . The PI permit inspection trial file database national international official control scientific authority , require . The PI review monitor complete CRFs database regular interval throughout trial .</detailed_description>
	<mesh_term>Syncope</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Sick Sinus Syndrome</mesh_term>
	<mesh_term>Syncope , Vasovagal</mesh_term>
	<criteria>Candidates must meet inclusion criterion require inclusion one two group ( summarize Table 2 ) . All patient need positive P wave &gt; 0.5 mm lead 2 . Patients must ≥ 1 syncope 6 month precede enrollment ≥ 2 syncope lifetime except last syncope complicate injury accident , case wait CardNM may less desirable . Patients &lt; 18 year must least 3 syncope interval exceed 1 month unless 1 syncope complicate injury accident . If significant rate drop ( &gt; 15 % ) note headup tilt test ( HUT ) , either isolate combined vasoplegia , associate syncope severe presyncope , patient eligible inclusion group A . If HUT negative pause &gt; 3 second document , patient assign group B . If condition present , patient eligible inclusion either group preferentially assign group A . Candidates exclude ANY follow criterion apply ( detailed Table 3 ) : &lt; 14 year age ; Inability provide consent ; Chronotropic negative medication ( excepted patient previous history atrial fibrillation ) ; 4 g amiodarone intake 2 month precede enrollment ; Alternating right bundle branch block ( RBBB ) leave bundle branch block ( LBBB ) , HV interval &gt; 70 m ; LBBB , bifascicular block ( RBBB + leave anterior hemiblock [ LAHB ] , RBBB + leave posterior hemiblock [ LPHB ] ) ; PR interval permanently &gt; 240 m ; Permanent AF , PAF electrical cardioversion last 6 month ; Valvular subvalvular aortic stenosis , mitral stenosis ; Any unstable medical condition , life expectancy &lt; 12 month ; Syncopes due noncardiac disease ( excepted NMS ) advance neuropathy ; Current pregnancy ; glaucoma . Patients transient atrioventricular conduction disturbance normal atrioventricular conduction exercise test normal QRS complex eligible study . Patients high risk bleed eligible , clopidogrel ( 75 mg daily , 1 month treatment ) prefer oral anticoagulant .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>cardio-neuromodulation</keyword>
	<keyword>cardio-neuroablation</keyword>
	<keyword>ablation</keyword>
	<keyword>ganglionated plexi</keyword>
	<keyword>anterior right ganglionated plexus</keyword>
	<keyword>syncope</keyword>
</DOC>